ESMO 2014

Oncology Meeting Resources

26 Sep - 30 Sep 2014, Madrid, Spain

ESMO 2014 Congress

The theme for ESMO 2014 was ‘Precision Medicine in Cancer Care.’ Whether you are a medical or surgical oncologist or a radiation oncologist, immunologist or pathologist, practising precision medicine means we are all working towards a common goal – improved patient outcomes. For your convenience and due to the large quantity of information coming from the ESMO 2014 congress, we have split the presentations up by main congress topic to allow you to find the information you need more easily.

Here, you will find the abstracts, posters, PDF presentation and webcasts from ESMO 2014 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Drug Index of ESMO 2014 Abstracts

Special Sessions and Tracks

Useful links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...cancer-mCRC-refractory-to-standard-therapies

AimTAS-102 is a combination of a novel oral nucleoside, trifluridine (FTD) with the thymidine phosphorylase inhibitor, tipiracil hydrochloride (TPI), which prevents the degradation of FTD, enabling sustained and effective FTD levels.

Date: 27 Sep 2014
Presenter: Eric Van Cutsem
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Supportive Care, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...-2014/Complications-arising-with-compliances

Date: 27 Sep 2014
Presenter: Andrea Antonuzzo
Resources: Presentation, Webcast
Topics: Complications of Treatment, Palliative and Supportive Care

http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Metabolic-disorders

Date: 27 Sep 2014
Presenter: Viktor Grünwald
Resources: Presentation, Webcast
Topic: Supportive Care

http://oncologypro.esmo.org/Meeting-Resourc...014/Organ-toxicities-from-targeted-therapies

Date: 27 Sep 2014
Presenter: Paolo Bossi
Resources: Presentation, Webcast
Topics: Complications of Treatment, Supportive Care

http://oncologypro.esmo.org/Meeting-Resourc...s-who-were-antenatal-exposed-to-radiotherapy

AimThe use of radiation in medical diagnostics and treatment is standard of care. Apart from deductions from atom bomb and nuclear plant disaster survivors, there are scarce data on the long-term outcome...

Date: 27 Sep 2014
Presenter: Frédéric Amant
Resources: Abstract
Topics: Complications of Treatment, Supportive Care, Cancer in Special Situations, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...Fertility-preservation-in-the-cancer-patient

Date: 27 Sep 2014
Presenter: Hamish Wallace
Resources: Presentation, Webcast
Topic: Supportive Care

http://oncologypro.esmo.org/Meeting-Resourc...cer-patients-receiving-bone-modifying-agents

AimBone-modifying agents (BMAs) reduce the incidence of skeletal-related events (SREs) and are recommended for breast cancer patients with bone metastasis. However, the risk factors for developing SREs,...

Date: 27 Sep 2014
Presenter: Ryota Tanaka
Resources: Abstract
Topics: Supportive Care, Breast Cancer, Metastatic

http://oncologypro.esmo.org/Meeting-Resourc...-predominant-metastatic-castration-resistant

BackgroundRa-223, a first-in-class alpha-radiopharmaceutical targeting bone metastases (mets), reduced risk of death by 30% and delayed time to first symptomatic skeletal event (SSE) versus placebo (15.

Date: 27 Sep 2014
Presenter: Matthew Smith
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Supportive Care, Prostate Cancer

http://oncologypro.esmo.org/Meeting-Resourc...of-nerve-sparing-radical-hysterectomy-RHE-S1

AimEvaluation of some indexes of urinary system function in patients with infiltrative cervical cancer (ICC) after surgical treatment.MethodsEvaluation of some indexes of urinary system function in...

Date: 27 Sep 2014
Presenter: Tetyana Dermenzhy
Resources: Abstract
Topics: Supportive Care, Cervical Cancer, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...reated-with-everolimus-A-retrospective-study

AimSarcopenia defined by a low SMI, has been identified as a prognostic factor in mRCC patients (pts) treated with tyrosine kinase inhibitors. Everolimus (Ev) has been approved in second- and third-line for mRCC.

Date: 27 Sep 2014
Presenter: Edouard Auclin
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Renal Cell Cancer, Supportive Care